), a global leader in medical devices used in critical care and
surgery, was recently awarded an innovative technology agreement by
Novation for the Arrow VPS Vascular Positioning System. The
agreement effective from September 1, 2012, encompasses the VPS
console and stylets, as well as pre-loaded stylets and is binding
through three years.
Teleflex was awarded the agreement via the innovative technology
evaluation process of Novation. Management at Teleflex is enthused
about its partnership with Novation to expand its product portfolio
riding on the back of innovative technologies. The agreement
underlines Teleflex's initiative to reduce vascular access
complications and improve quality of care.
Novation can collaborate with member councils and crew under its
Innovative Technology Program, to classify and analyze advanced or
innovative technology which enhances clinical benefit. The
company's Innovative Technology Program aims to cooperate with
hospital members who recognize its leading-edge technology.
The technology is capable of enhancing standards of care and may
curtail complications to patients or clinicians. The hallmark of an
innovative technology lies in its ability to improve patient care
The innovative technology of Arrow VPS is put down to its
TaperFree design which guarantees a homogeneous external diameter
along the length of the catheter. It has been clinically proven
that the use of Arrow VPS lowers the risk of thrombosis and other
complications owing to its unique features.
The use of Arrow VPS allows clinicians to discard the
requirement of an otherwise mandatory chest X-ray. This is due to
the novel intravascular Doppler, ECG and advanced algorithmic logic
to convey that the catheter tip has reached the desired location in
the vascular space.
Teleflex, headquartered in Limerick, Pennsylvania, is a
manufacturer and provider of medical devices used in critical care
and surgery. Its move to divest OEM Orthopedic division along with
the strategy of developing new, innovative products should help
improve its financial performance in the long run. The company's
focus on profitable and consistent growth with new product
introduction and portfolio expansion via acquisition is expected to
), which operate in similar business segments, present a tough
competitive landscape for Teleflex. Additionally, the company
operates in a stringent regulatory environment. The demand for its
products is susceptible to healthcare reimbursement systems in the
domestic as well as the international market.
Teleflex currently retains a Zacks #4 Rank, which translates
into a short-term Sell rating.
BARD C R INC (BCR): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.